Argenx Se (ARGX) Return on Equity ROE from the fourth quarter 2025 to fourth quarter 2024 and annually, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Argenx Se  (NASDAQ: ARGX)

Argenx Se's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Argenx Se in the fourth quarter 2025?
Argenx Se achieved a return on average equity (ROE) of 18.41 % in its fourth quarter 2025, this is above ARGX's average return on equity of -10.03%.
Argenx Ses equity during the 12 months ending in the fourth quarter 2025 are valued at $7 billion

ROE has advanced compared to 12.7% in the third quarter 2025, due to net income growth.

Within the Biotechnology & Pharmaceuticals industry 10 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from 0 to 773.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Equity Change 33.19 % 33.19 % 43.02 % 33.19 % -
Y / Y Net Income Change 55.1 % - - - -
Net Income (TTM) in Millions 1,292 833 833 833 833
Return On Equity (TTM) 18.41 % 12.7 % 13.65 % 14.76 % 16.05 %
ARGX's Total Ranking # 773 # 0 # # #
Equity (TTM) in Millions 7,323 7,323 6,096 7,323 5,498
Seq. Equity Change 0 % 20.13 % -16.76 % 33.19 % 0 %
Seq. Net Income Change - - - - -

Back to ARGX Management Effectiveness >> ARGX's 5 Years Annual ROE >> Compare ARGX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 11
Sector # 98
Overall # 773

Return On Equity Statistics
High Average Low
17.64 %
-10.03 %
-36.35 %
(Dec 31 2025)   (Dec 31 2020)





ARGX Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 7,323 5,498 4,098 2,814 2,534
Y / Y Equity Change 33.19 % 34.19 % 45.63 % 11.03 % 51.38 %
Net Income in Millions 1,292 833 -295 -710 -408
Y / Y Net Income Change 55.1 % - - - -
Return On Equity 17.64 % 15.15 % -7.2 % -25.22 % -16.11 %

Back to ARGX Management Effectiveness >> ARGX's 5 Years Annual ROE >> Compare ARGX ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 17.64 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ARGX's' Return on Equity at Yahoo Finance
ARGX's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ARGX's Competitors
Subscribers only: Roe for Argenx Se's Suppliers
Subscribers only: Return On Equity for ARGX's Customers




Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector ROE
Concentra Group Holdings Parent Inc   47.62 %
Theravance Biopharma inc   46.03 %
Galmed Pharmaceuticals Ltd   43.72 %
Acadia Pharmaceuticals Inc   41.90 %
Arrowhead Pharmaceuticals Inc   41.16 %
Gilead Sciences Inc   41.14 %
Tenet Healthcare Corp  40.89 %
Agilent Technologies inc   40.80 %
Bristol myers Squibb Company  39.17 %
Gsk Plc  38.67 %
Hutchmed china Limited  36.98 %
Oramed Pharmaceuticals Inc  36.81 %
Solventum Corporation  36.74 %
Newgenivf Group Limited  36.53 %
Merck and Co Inc   36.16 %
Adma Biologics Inc   34.98 %
Illumina Inc   34.94 %
Compugen Ltd  34.40 %
Vaxart Inc   33.83 %
Johnson and Johnson  33.78 %
Dexcom Inc   32.44 %
Phibro Animal Health Corporation  32.06 %
Innoviva Inc   30.60 %
Pro dex Inc   30.23 %
Novartis Ag  30.00 %
Incyte Corporation  29.15 %
Waters Corporation  28.52 %
Puma Biotechnology Inc   27.81 %
Resmed Inc   25.18 %
Encompass Health Corporation  24.76 %

Date modified: 2026-07-07T09:15:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.